Acrivastine

阿伐斯汀

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAcrivastine
Drug Alias Nameacrivastina阿化斯丁阿伐司汀acrivastineacrivastinum +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H1 receptor antagonists
TargetsHistamine H1 receptor
Therapy Area/IndicationsUrticariaRhinitis, Allergic, Seasonal
Global Approved IndicationsUrticariaRhinitis, Allergic, Seasonal
Approved Indications in ChinaUrticariaRhinitis, Allergic, Seasonal
Original Approved Country/TerritoryUnited States
Original Approved Date1988/01/01
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesWellcome Foundation Ltd
Inactive CompaniesN/A
Active IndicationsUrticariaRhinitis, Allergic, Seasonal
Inactive IndicationsN/A

Other Information

ATC CodeR06AX18
Related LinksWikipediaDrugBankKEGG